 |
| 02-May-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$123 → $119 |
|
| 06-Feb-13 | Reiterated |
Stifel Nicolaus |
Buy |
$110 → $118 |
|
| 06-Feb-13 | Reiterated |
Canaccord Genuity |
Hold |
$102 → $111 |
|
| 22-Jan-13 | Reiterated |
Canaccord Genuity |
Hold |
$101 → $102 |
|
| 19-Sep-12 | Initiated |
Canaccord Genuity |
Hold |
$101 |
|
| 30-Mar-12 | Reiterated |
RBC Capital Mkts |
Outperform |
$93 → $106 |
|
| 29-Mar-12 | Reiterated |
UBS |
Buy |
$100 → $107 |
|
| 29-Mar-12 | Reiterated |
Stifel Nicolaus |
Buy |
$90 → $110 |
|
| 01-Dec-11 | Upgrade |
Argus |
Hold → Buy |
$95 |
|
| 05-Oct-11 | Initiated |
JMP Securities |
Mkt Perform |
|
|
| 16-Sep-11 | Initiated |
Deutsche Bank |
Buy |
$97 |
|
| 05-May-11 | Reiterated |
UBS |
Buy |
$83 → $89 |
|
| 04-May-11 | Reiterated |
Collins Stewart |
Hold |
$75 → $85 |
|
| 03-Feb-11 | Reiterated |
RBC Capital Mkts |
Outperform |
$78 → $82 |
|
| 02-Nov-10 | Reiterated |
UBS |
Buy |
$78 → $83 |
|
| 18-Oct-10 | Reiterated |
RBC Capital Mkts |
Outperform |
$77 → $80 |
|
| 17-Sep-10 | Initiated |
RBC Capital Mkts |
Outperform |
$77 |
|
| 16-Jun-10 | Initiated |
Gleacher & Company |
Neutral |
|
|
| 04-Feb-10 | Reiterated |
Brean Murray |
Buy |
$75 → $70 |
|
| 17-Dec-09 | Initiated |
Brean Murray |
Buy |
$75 |
|
|
|
| 17-May-13 10:51AM | Allergan About To Put More Money In Your Pocket (AGN) at Forbes |
| 16-May-13 01:23PM | Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund, Interviews with The Wall Street Transcript: Investing in Health Care Innovation Wall Street Transcript |
| 01:04PM | AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward at TheStreet |
| 14-May-13 04:25PM | Why This Stock's Crash is a Buying Opportunity at Motley Fool |
| 11-May-13 01:04PM | ALLERGAN INC Financials EDGAR Online Financials |
| 10-May-13 09:18AM | New Stock Coverage: Frozen Smiles All Around at Allergan at Minyanville |
| 09:02AM | Should We Get Bullish on This Fast Growing Healthcare Company? at Motley Fool |
| 09-May-13 05:07PM | Obesity Surgery in India Spurs J&J Stomach-Staple Sales at Bloomberg |
| 08-May-13 05:01PM | Allergan Inc. (AGN): Today's Featured Drugs Laggard at TheStreet |
| 02:25PM | The Next Billionaire: A Statistician Who Changed Medicine at Forbes |
| 06:00AM | [video] 'Mad Money' Uncovered: Allergan at TheStreet |
| 06:00AM | [video] Mad Money Uncovered: Allergan at TheStreet |
| 07-May-13 07:33PM | Gastric banding: Pros and cons of Christie's surprising choice at Reuters |
| 06:02PM | What Gov. Christie's Secret Weight-Loss Surgery Means for Investors at Motley Fool |
| 04:55PM | Governor Christie Had Weight Loss Surgery in February at Bloomberg |
| 02:01PM | Christie's surgery could have helped Allergan shares, but alas.. at MarketWatch |
| 10:46AM | Cramer: Buy Discover Financial, Allergan, and These 2 Stocks, But Sell Cynosure at Wall St. Cheat Sheet |
| 09:43AM | ALLERGAN INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 07:00AM | Mad Money Uncovered: Allergan TheStreet.com TV |
| 06:46AM | Cramer's Lightning Round - EZChip Semiconductor Is Too Dicey (5/6/13) at Seeking Alpha |
| 06:46AM | Cramer's Lightning Round - EZchip Semiconductor Is Too Dicey (5/6/13) at Seeking Alpha |
| 06-May-13 06:30PM | Leading Biotechs Act Well But Be Careful Not To Chase at Investor's Business Daily |
| 04:00PM | Positive Opinion on Allergan Candidate Zacks |
| 03:27PM | Allergan: Is It Still Overvalued? at Seeking Alpha |
| 04-May-13 04:05PM | This Week in Biotech at Motley Fool |
| 04:30AM | It's Pipeline That Matters Most at TheStreet |
| 04:13AM | [$$] Charting the Market at Barrons.com |
| 03-May-13 06:58PM | [video] No Huddle Offense: What's Working In Pharma at CNBC |
| 06:04PM | Regeneron Pharma raises sales forecast for Eylea AP |
| 05:25PM | Regeneron Earnings Soar As Eylea Sales Skyrocket Investor's Business Daily |
| 01:45PM | Stocks Rally On Jobs Data; IBD 50 Names Assert Leadership at Investor's Business Daily |
| 01:12PM | S&P 500 Stocks Biggest Weekly Changes in Target Price at Bloomberg |
| 12:02PM | Higher Success Rates than Small-Molecule Drugs for Antibodies: Antibodies Display More Predictable Pharmacology and More Predictable Toxicity Profiles Wall Street Transcript |
| 11:22AM | Regeneron Stock Soars On Q1 Results, Guidance Hike at Investor's Business Daily |
| 11:07AM | Jim Cramer: Buy Allergan, Anadarko, and These 2 Solid Stocks at Wall St. Cheat Sheet |
| 01-May-13 08:30PM | Why Allergan's Pain Is Regeneron's Gain at Motley Fool -13.10% |
| 07:25PM | Maker of Botox Plunges the Most in 13 Years at Bloomberg |
| 06:58PM | [video] No Huddle Offense: Profits In the Pipeline? at CNBC |
| 06:09PM | NYSE stocks posting largest volume increases AP |
| 05:31PM | [video] Stock Pops & Drops at CNBC |
| 05:26PM | After the close: Allergan losses worsen, Humana gains on earnings at MarketWatch |
| 05:01PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 04:18PM | [$$] Allergan Reports Drug Development Delay, Lower Profits at The Wall Street Journal |
| 04:11PM | Stocks Pull Back In Higher Turnover, But Regeneron Soars at Investor's Business Daily |
| 04:00PM | Allergan Shares Cross Below 200 DMA at TheStreet |
| 04:00PM | [video] Tough Day for Stocks at CNBC |
| 03:58PM | Regeneron Soars To New High On Allergan's Test Delays at Investor's Business Daily |
| 03:54PM | Allergan's Very Bumpy Day at Barrons.com |
| 03:50PM | Allergan Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 03:39PM | Allergan slides, Regeneron surges on eye drug news AP |
| 02:51PM | Allergan shares fall on delay of eye drug study AP |
| 01:53PM | Stocks In Give-Back Mode; Spirit Air Flies, MasterCard Off at Investor's Business Daily |
| 01:46PM | Analysts: Allergans Offering Is Underappreciated, and 2 Other Research Notes to Browse at Wall St. Cheat Sheet |
| 01:45PM | [$$] Allergan Reports Drug Development Delay, Lower Profits at The Wall Street Journal |
| 01:18PM | NYSE stocks posting largest percentage decreases AP |
| 01:12PM | On The Fly: Midday Wrap at theflyonthewall.com |
| 12:44PM | Oversold Conditions For Allergan at TheStreet |
| 12:25PM | Allergan Beats on Earnings Zacks |
| 12:16PM | Weak Data Hamstrings Stocks; Regeneron Pharmaceuticals Soars at Investor's Business Daily |
| 12:16PM | Weak Data Hamstring Stocks; Regeneron Pharmaceuticals Soars at Investor's Business Daily |
| 12:11PM | UPDATE 1-Allergan delays eye drug, shares fall at Reuters |
| 11:51AM | Allergan falls, Regeneron jumps on speculation over vision-loss drug at MarketWatch |
| 11:48AM | Regeneron surges after Allergan says vision-loss drug delayed at theflyonthewall.com |
| 11:33AM | Allergan Shares Fall After CEO Says Drug Trial Will Be Delayed at Bloomberg |
| 11:32AM | Allergan says phase 2 data showed some differentiation between DARPin, Lucentis theflyonthewall.com |
| 11:30AM | U.S. Stock Options With Biggest Changes in Implied Volatility at Bloomberg |
| 11:17AM | BRIEF-Regeneron Pharma shares resume trading, up 16 percent at Reuters |
| 11:16AM | BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3 at Reuters |
| 11:11AM | Allergan falls, Regeneron jumps after Allergan comments on drug trial at theflyonthewall.com |
| 11:07AM | Allergan Evaluates Bids for its Lap-Band Weight Loss Product at Bloomberg |
| 10:56AM | Allergan retreats after lowering earnings guidance at theflyonthewall.com |
| 10:46AM | How the bears are playing Allergan optionMONSTER |
| 09:21AM | Strong Botox sales boost Allergan profit at Reuters |
| 09:00AM | Allergan Reports First Quarter 2013 Operating Results Business Wire |
| 07:07AM | Q1 2013 Allergan Earnings Release - Before Market Open CCBN |
| 02:31AM | ALLERGAN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 30-Apr-13 04:49PM | Scared of a Market Fall? Watch These Defensive Growth Stocks at Motley Fool |
| 12:59PM | Earnings Preview: Allergan shares up about 8% since reporting Q4 results at theflyonthewall.com |
| 09:53AM | FDA staff says Allergan's new dermal filler effective at Reuters |
| 09:00AM | Allergan Announces Death of Stephen J. Ryan, M.D. Business Wire |
| 08:32AM | FDA panel says Allergan's Juvederm data supports product effectiveness theflyonthewall.com |
| 29-Apr-13 07:00PM | Solvency II Rules Seen as Costing U.K. Insurers $310 Million at Bloomberg |
| 05:00PM | Allergan Inc. (AGN): Today's Featured Drugs Winner at TheStreet |
| 11:26AM | Forbes Earnings Preview: Allergan at Forbes |
| 10:28AM | Jim Cramer: Buy Allergan, Buy AIG, Buy These 2 Solid Stocks at Wall St. Cheat Sheet |
| 28-Apr-13 05:00PM | Does This Common Vegetable Hold the Migraine Cure? at Motley Fool |
| 26-Apr-13 06:00PM | Jim Cramer: Mid-Week Sell-Off Potential Ahead at CNBC |
| 06:00PM | Cramer's Game Plan: Mid-Week Sell-Off Ahead? at CNBC |
| 06:00PM | Cramer's Game Plan: Mid-Week Selloff Ahead? at CNBC |
| 05:48PM | [$$] FDA Warns of Counterfeit Botox at The Wall Street Journal |
| 05:02PM | Stocks Mostly Lower Friday, But End Week With Gains at Investor's Business Daily |
| 03:28PM | UPDATE 2-Fraudulent versions of Allergan's Botox found in the U.S. at Reuters |
| 02:41PM | UPDATE 1-Fraudulent wrinkle-filler Botox found in the U.S. at Reuters |
| 02:08PM | Counterfeit wrinkle-filler Botox discovered in the United States at Reuters |
| 11:48AM | Wall Street Transcript Interview with Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY) Wall Street Transcript |
| 25-Apr-13 03:46PM | Allergan Becomes #137 Most Shorted S&P 500 Component, Replacing Harley-Davidson at Forbes |
| 24-Apr-13 01:03PM | 5 Stocks Pulling The Health Care Sector Downward at TheStreet |
| 23-Apr-13 07:01PM | UK review warns on cosmetic injections, urges tougher rules at Reuters |
| 07:01PM | Cosmetic Procedures Need Tighter Restrictions: U.K. Panel at Bloomberg |
| 03:22AM | Dutch Mortgage-Bond Market Threatened by Capital Rules, DSA Says at Bloomberg |
|
|
| Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and over-the-counter skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, urologists, and general practitioners. The company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Jones Trevor M | Director | May 15 | Option Exercise | 36.49 | 1,000 | 36,490 | 14,142 | May 17 03:48 PM | | Jones Trevor M | Director | May 15 | Sale | 103.40 | 2,000 | 206,800 | 12,142 | May 17 03:48 PM | | EDWARDS JEFFREY L | EVP, Fin & Bus. Dev., CFO | May 09 | Option Exercise | 58.55 | 40,100 | 2,347,855 | 56,971 | May 10 08:54 PM | | EDWARDS JEFFREY L | EVP, Fin & Bus. Dev., CFO | May 09 | Sale | 103.72 | 40,100 | 4,159,280 | 16,871 | May 10 08:54 PM | | EDWARDS JEFFREY L | EVP, Fin & Bus. Dev., CFO | May 08 | Option Exercise | 57.14 | 43,900 | 2,508,545 | 60,771 | May 10 08:54 PM | | EDWARDS JEFFREY L | EVP, Fin & Bus. Dev., CFO | May 08 | Sale | 103.29 | 43,900 | 4,534,229 | 16,871 | May 10 08:54 PM | | Jones Trevor M | Director | Apr 15 | Option Exercise | 60.60 | 1,000 | 60,600 | 12,327 | Apr 16 09:29 PM | | Jones Trevor M | Director | Apr 15 | Sale | 115.74 | 2,000 | 231,480 | 10,327 | Apr 16 09:29 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Apr 11 | Option Exercise | 36.15 | 12,005 | 433,981 | 29,332 | Apr 15 04:00 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Apr 11 | Sale | 115.00 | 12,005 | 1,380,575 | 17,327 | Apr 15 04:00 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Apr 03 | Option Exercise | 36.15 | 13,195 | 476,999 | 30,522 | Apr 05 05:05 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Apr 03 | Sale | 115.00 | 13,195 | 1,517,425 | 17,327 | Apr 05 05:05 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Mar 26 | Option Exercise | 36.15 | 11,484 | 415,147 | 28,811 | Mar 27 07:11 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Mar 26 | Sale | 112.00 | 11,484 | 1,286,208 | 17,327 | Mar 27 07:11 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Mar 25 | Option Exercise | 36.15 | 4,925 | 178,039 | 22,252 | Mar 25 06:41 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Mar 25 | Sale | 112.00 | 4,925 | 551,600 | 17,327 | Mar 25 06:41 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Mar 21 | Option Exercise | 36.15 | 1,191 | 43,055 | 18,518 | Mar 25 06:41 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Mar 21 | Sale | 112.00 | 1,191 | 133,392 | 17,327 | Mar 25 06:41 PM | | Jones Trevor M | Director | Mar 15 | Option Exercise | 60.60 | 1,000 | 60,600 | 13,327 | Mar 18 07:47 PM | | Jones Trevor M | Director | Mar 15 | Sale | 108.68 | 2,000 | 217,360 | 11,327 | Mar 18 07:47 PM | | RYAN STEPHEN J | Director | Mar 05 | Option Exercise | 60.60 | 5,700 | 345,420 | 10,970 | Mar 06 05:35 PM | | RYAN STEPHEN J | Director | Mar 05 | Sale | 110.00 | 5,700 | 627,000 | 5,270 | Mar 06 05:35 PM | | Jones Trevor M | Director | Feb 15 | Option Exercise | 60.60 | 1,000 | 60,600 | 14,327 | Feb 19 09:28 PM | | Jones Trevor M | Director | Feb 15 | Sale | 107.82 | 2,000 | 215,640 | 12,327 | Feb 19 09:28 PM | | Jones Trevor M | Director | Jan 15 | Option Exercise | 60.60 | 1,000 | 60,600 | 15,327 | Jan 16 05:50 PM | | RYAN STEPHEN J | Director | Jan 15 | Option Exercise | 60.60 | 5,700 | 345,420 | 10,970 | Jan 16 05:47 PM | | Jones Trevor M | Director | Jan 15 | Sale | 103.30 | 2,000 | 206,600 | 13,327 | Jan 16 05:50 PM | | RYAN STEPHEN J | Director | Jan 15 | Sale | 103.30 | 5,700 | 588,810 | 5,270 | Jan 16 05:47 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Jan 04 | Option Exercise | 41.24 | 24,000 | 989,760 | 46,979 | Jan 07 07:16 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Jan 04 | Sale | 96.80 | 24,000 | 2,323,200 | 22,979 | Jan 07 07:16 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Dec 07 | Option Exercise | 30.13 | 6,800 | 204,850 | 29,779 | Dec 11 07:50 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Dec 07 | Sale | 91.23 | 6,800 | 620,391 | 22,979 | Dec 11 07:50 PM | | Endicott David J. | CVP and President, AGN Med | Nov 29 | Option Exercise | 64.47 | 52,560 | 3,388,543 | 72,912 | Nov 30 05:33 PM | | Endicott David J. | CVP and President, AGN Med | Nov 29 | Sale | 92.43 | 52,560 | 4,857,974 | 20,352 | Nov 30 05:33 PM | | GALLAGHER MICHAEL R | Director | Nov 28 | Option Exercise | 51.32 | 9,768 | 501,270 | 18,568 | Nov 28 08:16 PM | | Gangolli Julian S | CVP & Pres, North America | Nov 28 | Option Exercise | 58.55 | 55,378 | 3,242,382 | 71,159 | Nov 29 07:55 PM | | Gangolli Julian S | CVP & Pres, North America | Nov 28 | Sale | 91.66 | 55,378 | 5,075,947 | 15,781 | Nov 29 07:55 PM | | GALLAGHER MICHAEL R | Director | Nov 28 | Sale | 91.68 | 3,598 | 329,866 | 27,600 | Nov 28 08:16 PM | | GALLAGHER MICHAEL R | Director | Nov 28 | Sale | 91.29 | 9,768 | 891,675 | 8,800 | Nov 28 08:16 PM | | GALLAGHER MICHAEL R | Director | Nov 27 | Option Exercise | 44.01 | 20,632 | 907,964 | 29,432 | Nov 28 08:16 PM | | Gangolli Julian S | CVP & Pres, North America | Nov 27 | Option Exercise | 42.62 | 34,622 | 1,475,418 | 50,403 | Nov 29 07:55 PM | | Gangolli Julian S | CVP & Pres, North America | Nov 27 | Sale | 92.25 | 34,622 | 3,193,994 | 15,781 | Nov 29 07:55 PM | | GALLAGHER MICHAEL R | Director | Nov 27 | Sale | 91.93 | 11,802 | 1,084,979 | 31,198 | Nov 28 08:16 PM | | GALLAGHER MICHAEL R | Director | Nov 27 | Sale | 92.07 | 20,632 | 1,899,545 | 8,800 | Nov 28 08:16 PM | | Jones Trevor M | Director | Nov 26 | Option Exercise | 60.60 | 1,000 | 60,600 | 16,827 | Nov 27 08:06 PM | | Jones Trevor M | Director | Nov 26 | Sale | 91.30 | 2,500 | 228,250 | 14,327 | Nov 27 08:06 PM | | GALLAGHER MICHAEL R | Director | Nov 26 | Sale | 91.20 | 4,700 | 428,657 | 43,000 | Nov 28 08:16 PM | | RAY RUSSELL T | Director | Nov 21 | Option Exercise | 39.74 | 15,000 | 596,125 | 37,800 | Nov 26 06:27 PM | | HUDSON DAWN E | Director | Nov 21 | Sale | 91.00 | 5,000 | 455,000 | 18,800 | Nov 21 03:17 PM | | RAY RUSSELL T | Director | Nov 21 | Sale | 91.05 | 33,000 | 3,004,565 | 22,800 | Nov 26 06:27 PM | | Diradoorian Raymond H | EVPGlobal Technical Operations | Nov 20 | Option Exercise | 55.98 | 25,000 | 1,399,375 | 31,521 | Nov 21 03:25 PM | | EDWARDS JEFFREY L | EVP, Fin & Bus. Dev., CFO | Nov 20 | Option Exercise | 55.98 | 60,000 | 3,358,500 | 76,072 | Nov 21 03:34 PM | | EDWARDS JEFFREY L | EVP, Fin & Bus. Dev., CFO | Nov 20 | Sale | 90.95 | 59,000 | 5,366,121 | 17,072 | Nov 21 03:34 PM | | Diradoorian Raymond H | EVPGlobal Technical Operations | Nov 20 | Sale | 91.02 | 25,000 | 2,275,585 | 6,521 | Nov 21 03:25 PM | | Jones Trevor M | Director | Oct 26 | Option Exercise | 60.60 | 1,000 | 60,600 | 18,327 | Oct 29 08:16 PM | | Jones Trevor M | Director | Oct 26 | Sale | 91.30 | 2,500 | 228,250 | 15,827 | Oct 29 08:16 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Oct 17 | Option Exercise | 30.13 | 5,000 | 150,625 | 27,979 | Oct 18 05:12 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Oct 17 | Sale | 94.70 | 5,000 | 473,500 | 22,979 | Oct 18 05:12 PM | | PYOTT DAVID E I | Chairman, President and CEO | Oct 05 | Option Exercise | 41.24 | 307,956 | 12,700,105 | 537,052 | Oct 05 07:21 PM | | PYOTT DAVID E I | Chairman, President and CEO | Oct 05 | Sale | 93.72 | 307,956 | 28,862,868 | 229,096 | Oct 05 07:21 PM | | PYOTT DAVID E I | Chairman, President and CEO | Oct 04 | Option Exercise | 36.99 | 311,044 | 11,504,770 | 330,517 | Oct 05 07:21 PM | | PYOTT DAVID E I | Chairman, President and CEO | Oct 04 | Sale | 93.73 | 308,344 | 28,901,200 | 19,473 | Oct 05 07:21 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Oct 01 | Option Exercise | 30.13 | 6,000 | 180,750 | 28,979 | Oct 02 08:11 PM | | Whitcup Scott M | Executive VP, R&D, CSO | Oct 01 | Sale | 92.70 | 6,000 | 556,200 | 22,979 | Oct 02 08:11 PM | | Jones Trevor M | Director | Sep 26 | Option Exercise | 60.60 | 1,000 | 60,600 | 18,327 | Sep 27 06:07 PM | | Jones Trevor M | Director | Sep 26 | Sale | 91.92 | 2,500 | 229,800 | 17,327 | Sep 27 06:07 PM | | Jones Trevor M | Director | Sep 12 | Option Exercise | 60.60 | 1,000 | 60,600 | 19,827 | Sep 13 08:30 PM | | Jones Trevor M | Director | Sep 12 | Sale | 90.00 | 1,000 | 90,000 | 18,827 | Sep 13 08:30 PM | | INGRAM DOUGLAS S | EVP and President, EAME | Aug 30 | Option Exercise | 36.15 | 100,000 | 3,615,000 | 124,183 | Aug 31 05:41 PM | | INGRAM DOUGLAS S | EVP and President, EAME | Aug 30 | Sale | 85.78 | 100,000 | 8,578,230 | 24,183 | Aug 31 05:41 PM | | LAVIGNE LOUIS J JR | Director | Aug 29 | Sale | 85.04 | 15,000 | 1,275,600 | 5,400 | Aug 30 08:19 PM | | Jones Trevor M | Director | Aug 27 | Sale | 85.43 | 1,500 | 128,145 | 18,827 | Aug 28 08:17 PM | | RYAN STEPHEN J | Director | Aug 07 | Option Exercise | 48.83 | 15,900 | 776,364 | 64,352 | Aug 07 08:58 PM | | RYAN STEPHEN J | Director | Aug 07 | Sale | 85.35 | 15,900 | 1,356,989 | 48,452 | Aug 07 08:58 PM | | RYAN STEPHEN J | Director | Aug 06 | Option Exercise | 52.85 | 15,900 | 840,243 | 64,352 | Aug 07 08:58 PM | | RYAN STEPHEN J | Director | Aug 06 | Sale | 85.47 | 15,900 | 1,358,928 | 48,452 | Aug 07 08:58 PM | | RYAN STEPHEN J | Director | Aug 03 | Option Exercise | 39.74 | 15,000 | 596,125 | 63,452 | Aug 07 08:58 PM | | RYAN STEPHEN J | Director | Aug 03 | Sale | 86.50 | 15,000 | 1,297,556 | 48,452 | Aug 07 08:58 PM | | Jones Trevor M | Director | Aug 01 | Option Exercise | 60.60 | 1,000 | 60,600 | 21,327 | Aug 03 07:45 PM | | Jones Trevor M | Director | Aug 01 | Sale | 90.00 | 1,000 | 90,000 | 20,327 | Aug 03 07:45 PM | | Jones Trevor M | Director | Jul 26 | Sale | 84.70 | 1,500 | 127,050 | 20,327 | Jul 27 06:34 PM | | Jones Trevor M | Director | Jun 26 | Option Exercise | 60.60 | 1,000 | 60,600 | 22,827 | Jun 27 06:09 PM | | Jones Trevor M | Director | Jun 26 | Sale | 90.02 | 2,500 | 225,060 | 21,827 | Jun 27 06:09 PM | | Whitcup Scott M | Executive VP, R&D, CSO | May 30 | Option Exercise | 30.13 | 1,500 | 45,188 | 24,479 | May 31 06:35 PM | | Whitcup Scott M | Executive VP, R&D, CSO | May 30 | Sale | 90.71 | 1,500 | 136,062 | 22,979 | May 31 06:35 PM | | Jones Trevor M | Director | May 29 | Option Exercise | 51.72 | 1,000 | 51,715 | 24,327 | May 30 08:44 PM | | Jones Trevor M | Director | May 29 | Sale | 91.13 | 2,500 | 227,830 | 23,327 | May 30 08:44 PM |
|
|
|
|
|
|
